Upstream Bio, Inc. (UPB)

Upstream Bio's stock price has fluctuated significantly in the past six months, trending down by 60.41%. A notable drop of 47% occurred after mixed results from the Phase 2 VALIANT trial. The stock saw a +3.38% change when the company highlighted its Phase 3 development strategy and reported financial results. A -1.09% change was related to the announcement of presenting new data from the Phase 2 VIBRANT trial.

As a clinical-stage biotechnology company, traditional demand seasonality is not applicable. The company's focus is on research, development, and advancing its drug candidate through regulatory processes.

Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. Their lead product, verekitug, is a novel monoclonal antibody targeting TSLP, a key driver of inflammatory responses. Verekitug is currently in Phase 2 clinical trials for severe asthma, CRSwNP, and COPD.

Upstream Bio is headquartered in Waltham, Massachusetts, USA. While primarily based in the U.S., its clinical trials are global, and it collaborates with partners across several regions.

Information specifically detailing Upstream Bio's brand reputation is not readily available. News primarily focuses on clinical trial progress, financial results, and corporate announcements.

Upstream Bio's ownership is a mix of institutional, insider, and retail investors. Institutional investors hold approximately 21.05% to 29.01% of the stock, insiders hold 8.69%, and retail investors hold 62.30%. Major institutional owners include Fmr Llc, Orbimed Advisors Llc, and BlackRock, Inc. Erez Chimovits owns the most shares among insiders.